IP Library Granted Patent US 8,173,779
Granted Patent B2
US 8,173,779 · App. 12/941,617 · Granted May 8, 2012

Neutralizing human anti-IGFR antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,779
App. No.
12/941,617
Granted
May 8, 2012
Kind
B2
Abstract

The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Claims (16)

1. An isolated antibody or antigen binding fragment thereof produced by a method comprising introducing a polynucleotide encoding a polypeptide that comprises amino acids 20-137 of SEQ ID NO: 45 and a polynucleotide encoding a polypeptide that comprises amino acids 20-128 of SEQ ID NO: 78 into a host cell under conditions wherein said antibody or fragment are produced in said host cell.

2. The antibody or fragment of claim 1 wherein the host cell is a eukaryotic cell.

3. The antibody or fragment of claim 2 wherein said host cell is Chinese hamster ovary cell.

4. The antibody or fragment of claim 2 wherein the host cell is a fungal cell.

5. The antibody or fragment of claim 1 wherein said polypeptides are isolated from said cell.

6. The antibody or fragment of claim 1 wherein a polynucleotide encoding a polypeptide is operably associated with a CMV promoter.

7. The antibody or fragment of claim 1 wherein the polynucleotides are in a vector.

8. The antibody or fragment of claim 7 wherein the vector comprises a DHFR gene.

9. The antibody or frayment of claim 8 wherein the DHFR gene is operably linked to a mouse mammary tumor virus long terminal repeat promoter.

10. The antibody or fragment of claim 7 wherein the vector comprises a hygromycin B gene.

11. The antibody or fragment of claim 10 wherein the hygromycin B gene is operably linked to a TK promoter.

12. The antibody or fragment of claim 1 wherein the method comprises introducing one or more vectors comprising one or more polynucleotides encoding said polypeptides, operably linked to a CMV promoter, into a Chinese hamster ovary cell under conditions wherein said antibody or fragment is produced in said host cell and isolating said polypeptides.

13. The antibody or fragment of claim 12 wherein a vector comprises a DHFR gene.

14. The antibody or fragment of claim 13 wherein the DHFR gene is operably linked to a mouse mammary tumor virus long terminal repeat promoter.

15. The antibody or fragment of claim 14 wherein a vector comprises a hygromycin B gene.

16. The antibody or fragment of claim 15 wherein the hygromycin B gene is operably linked to a TK promoter.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →